Last updated: May 20, 2022
Sponsor: Axem Neurotechnology Inc.
Overall Status: Active - Recruiting
Phase
1
Condition
N/ATreatment
N/AClinical Study ID
NCT05258591
2020A016951
Ages 18-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 18 - 90 years
- 6 months - 5 years since most recent stroke
- Upper-extremity Fugl-Meyer motor function (FMA-UE) score ≤56
- Able to follow simple commands
- Fluency in English
- Not currently receiving therapy for the upper extremity
Exclusion
Exclusion Criteria:
- Visual impairment that would interfere with visualization of the therapy interface (score >0 on the visual subscale of the NIH stroke scale)
- Montreal Cognitive Assessment (MoCA) Score ≥10
- History of significant physical disability prior to most recent stroke
- Open wounds on the scalp
- Unable or unwilling to remove hair braids or head coverings which interfere with theAxem Home device efficacy.
- Inability to follow training instructions for at-home BCI system.
Study Design
Total Participants: 40
Study Start date:
February 23, 2022
Estimated Completion Date:
February 29, 2024
Connect with a study center
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.